ORJEMSA
DEAD

Serial Number

97591746

Owner

DAY ONE BIOPHARMACEUTICALS, INC.

Attorney

Connie L. Ellerbach

Filing Date

Sep 14, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ORJEMSA Trademark

Serial Number: 97591746

ORJEMSA is a trademark filed by DAY ONE BIOPHARMACEUTICALS, INC. on September 14, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

DAY ONE BIOPHARMACEUTICALS, INC. (17 trademarks)

1800 Sierra Point Parkway, Suite 200
Brisbane, CA 94005

Entity Type: 03

Trademark Details

Filing Date

September 14, 2022

Registration Date

Not Registered

Published for Opposition

May 21, 2024

Goods & Services

Pharmaceutical preparations for human use for the treatment of cancer; pharmaceutical preparation for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of oncological diseases; pharmaceutical preparations and substances for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system diseases and disorders; targeted pharmaceutical preparations for use in cancer prevention and treatment; pharmaceutical and veterinary preparations for the delivery of compounds to the body for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system diseases and disorders

Medical information services; healthcare services; healthcare services, namely, providing cancer treatment information to physicians, health care professionals, and patients; medical information services, namely, providing information regarding viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system diseases and disorders

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Feb 17, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Feb 17, 2025 ABN6
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 10, 2025 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 10, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 10, 2025 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 16, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 21, 2024 NPUB
PUBLISHED FOR OPPOSITION
May 21, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 1, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 18, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 5, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 4, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Apr 4, 2024 ERFR
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jan 2, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jan 2, 2024 XELR
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 10, 2023 GNFN
FINAL REFUSAL E-MAILED
Oct 10, 2023 GNFR
FINAL REFUSAL WRITTEN
Oct 10, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 12, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 11, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 11, 2023 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jun 6, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jun 6, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 10, 2023 GNRN
NON-FINAL ACTION E-MAILED
Mar 10, 2023 GNRT
NON-FINAL ACTION WRITTEN
Mar 10, 2023 CNRT
ASSIGNED TO EXAMINER
Mar 7, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 29, 2022 NWOS
NEW APPLICATION ENTERED
Sep 17, 2022 NWAP